Simply Wall St.
Regeneron Allergy Antibodies And Dupixent Data Reframe Growth Prospects
📈
AI Sentiment
Highly Positive
8/10
- Home
- REGN
as of 02-13-2026 3:46pm EST
$798.79
+$15.14
+1.93%
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 79.4B | IPO Year: | 1991 |
| Target Price: | $812.57 | AVG Volume (30 days): | 885.1K |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 41.48 | EPS Growth: | 8.19 |
| 52 Week Low/High: | $476.49 - $821.11 | Next Earning Date: | 01-30-2026 |
| Revenue: | $14,342,900,000 | Revenue Growth: | 0.99% |
| Revenue Growth (this year): | 10.39% | Revenue Growth (next year): | 9.73% |
| P/E Ratio: | 19.36 | Index: | |
| Free Cash Flow: | 4.1B | FCF Growth: | +11.35% |
AI-Powered REGN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 4 days ago
AI Recommendation
hold
Model Accuracy: 72.67%
72.67%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Regeneron Pharmaceuticals Inc. (REGN)
Pitofsky Jason
Sell
SVP Controller
REGN Feb 9, 2026
Avg Cost/Share
$780.50
Shares
2,036
Total Value
$1,585,058.14
Owned After
4,325
RYAN ARTHUR F
Sell
Director
REGN Feb 9, 2026
Avg Cost/Share
$781.51
Shares
100
Total Value
$77,852.60
Owned After
17,803
Bassler Bonnie L
Sell
Director
REGN Jan 7, 2026
Avg Cost/Share
$800.00
Shares
1,500
Total Value
$1,200,000.00
Owned After
1,703
SEC Form 4
Bassler Bonnie L
Sell
Director
REGN Nov 20, 2025
Avg Cost/Share
$750.00
Shares
760
Total Value
$570,000.00
Owned After
1,703
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Pitofsky Jason | REGN | SVP Controller | Feb 9, 2026 | Sell | $780.50 | 2,036 | $1,585,058.14 | 4,325 | |
| RYAN ARTHUR F | REGN | Director | Feb 9, 2026 | Sell | $781.51 | 100 | $77,852.60 | 17,803 | |
| Bassler Bonnie L | REGN | Director | Jan 7, 2026 | Sell | $800.00 | 1,500 | $1,200,000.00 | 1,703 | |
| Bassler Bonnie L | REGN | Director | Nov 20, 2025 | Sell | $750.00 | 760 | $570,000.00 | 1,703 |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
Insider Monkey
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating
📊
AI Sentiment
Positive
7/10
StockStory
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges
📊
AI Sentiment
Positive
6/10
Investor's Business Daily
Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson
📉
AI Sentiment
Negative
3/10
Compare REGN vs Leading Stocks
See how REGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.